Fursultiamine (Vitamin B1) injections 50 mg from Japan (fatigue, anxiety, weakness)
Product Code :
Availability : 8
General information about Japanese Fursultiamine (Vitamin B1) injections 50 mg
Package details: 50 ampoules
Manufacturer: Nisshin Pharmaceutical, Japan.
Active ingredient: Fursultiamine 50 mg in each ampoule
Medical effect: Fursultiamine (Vitamin B1) injections 50 mg are effective for treatment of vitamin B1 deficiency. They also help to treat such symptoms of thiamine deficiency as:
- fatigue, tiredness,
- poor memory,
- muscle weakness,
- blurry vision,
- irritability, anxiety,
- shortness of breath,
- heart rate abnormality,
- sleep disturbance.
Contraindications and precautions: do not use in pregnant or breastfeeding women. When used with other drugs, be sure to consult with your doctor to avoid the interaction between the medicines.
Dosage and Administration of Fursultiamine (Vitamin B1) injections 50 mg from Japan: inject by intravenous injection (IV), for adults 50-100 mg of active ingredient a day.
Regarding the effectiveness of Japanese Fursultiamine (Vitamin B1) injections 50 mg
Vitamin B1 deficiency might provoke various symptoms, from muscle weakness, fatigue, poor sleep and memory to problems with heart rate, vision and breath. Fursultiamine is a Vitamin B1 derivative with improved lipophilicity first synthetized in Japan in 1960s. Fursultiamine (Vitamin B1) injections 50 mg from Japan are effective for prevention of the thiamine deficiency, improving sleep, breath, vision and heart rate, treatment of the chronic fatigue and muscle weakness. Studies also show that Fursultiamine has a great potential in treatment of gastrointestinal problems and Alzheimer’s disease (Y. Suzuki, H. Itoh et al. “Comparison of the effects of pantethine and fursultiamine on plasma gastrointestinal peptide levels in healthy volunteers”. Biological and Pharmaceutical Bulletin, 2011; 34(10): 1640-3; Y. Mimori, H. Katsuoka, S. Nakamura. “Thiamine therapy in Alzheimer's disease”. Metabolic brain disease, 1996, 11(1): 89-94).